

Wright Medical Group, Inc.
Reconciliation of Net Sales to Net Sales Excluding the Impact of Foreign Currency
(dollars in thousands--unaudited)

	<u>Three Months Ended September 30, 2006</u>	<u>Nine Months Ended September 30, 2006</u>
Net sales, as reported	\$ 78,637	\$ 252,385
Currency impact as compared to prior period	(505)	1,767
Net sales, excluding the impact of foreign currency	<u>\$ 78,132</u>	<u>\$ 254,152</u>

Wright Medical Group, Inc.
Reconciliation of Non-GAAP Results of Operations
(in thousands, except per share data--unaudited)

	<u>Three Months Ended September 30, 2006</u>			<u>Three Months Ended September 30, 2005</u>		
	<u>As Reported</u>	<u>Non-GAAP Adjust- ments (a)</u>	<u>As Adjusted</u>	<u>As Reported</u>	<u>Non-GAAP Adjust- ments (a)</u>	<u>As Adjusted</u>
Net sales	\$78,637	\$ -	\$ 78,637	\$73,479	\$ -	\$73,479
Cost of sales	22,517	(258) (b)	22,259	20,263	-	20,263
Gross profit	56,120	258	56,378	53,216	-	53,216
Operating expenses:						
Selling, general and administrative	45,494	(2,845) (b)	42,649	40,110	(65) (b)	40,045
Research and development	6,175	(556) (b)	5,619	5,904	-	5,904
Amortization of intangible assets	987	-	987	1,020	-	1,020
Total operating expenses	52,656	(3,401)	49,255	47,034	(65)	46,969
Operating income	3,464	3,659	7,123	6,182	65	6,247
Interest (income) expense, net	(570)	-	(570)	(171)	-	(171)
Other expense (income), net	(1,550)	1,499 (c)	(51)	43	-	43
Income before income taxes	5,584	2,160	7,744	6,310	65	6,375
Provision for income taxes	1,979	823 (d)	2,802	2,324	26 (d)	2,350
Net income	<u>\$3,605</u>	<u>\$ 1,337</u>	<u>\$ 4,942</u>	<u>\$3,986</u>	<u>\$ 39</u>	<u>\$ 4,025</u>
Net income per share, basic	<u>\$ 0.10</u>	<u>\$ 0.04</u>	<u>\$ 0.14</u>	<u>\$ 0.12</u>	<u>\$ 0.00</u>	<u>\$ 0.12</u>
Net income per share, diluted	<u>\$ 0.10</u>	<u>\$ 0.04</u>	<u>\$ 0.14</u>	<u>\$ 0.11</u>	<u>\$ 0.00</u>	<u>\$ 0.11</u>
Weighted-average number of common shares outstanding, basic	<u>34,420</u>	<u>-</u>	<u>34,420</u>	<u>33,972</u>	<u>-</u>	<u>33,972</u>
Weighted-average number of common shares outstanding, diluted	<u>35,460</u>	<u>8</u>	<u>35,468</u>	<u>35,285</u>	<u>-</u>	<u>35,285</u>

	Nine Months Ended September 30, 2006			Nine Months Ended September 30, 2005		
	As Reported	Non-GAAP Adjust- ments (a)	As Adjusted	As Reported	Non-GAAP Adjust- ments (a)	As Adjusted
Net sales	\$ 252,385	\$ -	\$ 252,385	\$ 238,869	\$ -	\$ 238,869
Cost of sales	72,245	(487) (b)	71,758	67,409	(11) (b)	67,398
Gross profit	180,140	487	180,627	171,460	11	171,471
Operating expenses:						
Selling, general and administrative	143,396	(8,007) (b)	135,389	121,276	(380) (b)	120,896
Research and development	19,994	(1,627) (b)	18,367	16,505	(5) (b)	16,500
Amortization of intangible assets	3,254	-	3,254	3,119	-	3,119
Total operating expenses	166,644	(9,634)	157,010	140,900	(385)	140,515
Operating income	13,496	10,121	23,617	30,560	396	30,956
Interest (income) expense, net	(1,188)	-	(1,188)	(91)	-	(91)
Other expense (income), net	(1,483)	1,499 (c)	16	206	-	206
Income before income taxes	16,167	8,622	24,789	30,445	396	30,841
Provision for income taxes	7,503	2,054 (d)	9,557	11,423	157 (d)	11,580
Net income	\$ 8,664	\$ 6,568	\$ 15,232	\$ 19,022	\$ 239	\$ 19,261
Net income per share, basic	\$ 0.25	\$ 0.19	\$ 0.44	\$ 0.56	\$ 0.01	\$ 0.57
Net income per share, diluted	\$ 0.25	\$ 0.18	\$ 0.43	\$ 0.54	\$ 0.01	\$ 0.55
Weighted-average number of common shares outstanding, basic	34,289	-	34,289	33,920	-	33,920
Weighted-average number of common shares outstanding, diluted	35,319	(16)	35,303	35,240	-	35,240

(a) These Non-GAAP adjustments reconcile the Company's GAAP results of operations to its as adjusted results of operations.

(b) These adjustments reflect non-cash stock based compensation.

(c) These adjustments reflect the third quarter of 2006 gain from the sale of an investment.

(d) These adjustments reflect the tax impact of the above noted non-GAAP adjustments.